NCT07412197 (PREVENT-Lynch) is a Phase 1/Phase 2 clinical trial of DC vaccination in Lynch Syndrome, sponsored by Radboud University Medical Center.

Who is sponsoring NCT07412197?

NCT07412197 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT07412197?

Interventions in NCT07412197: DC vaccination.

What condition does NCT07412197 study?

NCT07412197 studies Lynch Syndrome.

Is NCT07412197 still recruiting?

NCT07412197 is currently not yet recruiting. Last updated 30 April 2026.

Last reviewed 2026-04-30 · How we verify

NCT07412197: PREVENT-Lynch

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Targeting Cancer Neoantigens Through Multi-Epitope Vaccination for Tumour Prevention in Lynch Syndrome: a Phase I/II Clinical Trial.

Not yet recruiting Phase 1/Phase 2 Last updated 30 April 2026

What this trial tests

Phase 1/Phase 2 trial testing DC vaccination in Lynch Syndrome in 13 participants. Not yet recruiting.

Timeline

1 August 2026

Primary endpoint
1 December 2029

1 June 2036

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	Phase 1/Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	13
Start date	1 August 2026
Primary completion	1 December 2029
Estimated completion	1 June 2036
Sites	1 location across Netherlands

Drugs / interventions tested

DC vaccination — full drug profile →

Conditions studied

Lynch Syndrome — all drugs for Lynch Syndrome →

Sponsor

Radboud University Medical Center

Who can join

Adults 35 to 75, any sex, with Lynch Syndrome. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of participants successfully enrolled for manufacturing autologous DC product with sufficient yield for at least one injection intranodally (IN) for treatment purposes and one intradermally (ID) for diagnostic purposes(Feasibility)
Time frame: 2 years
Number of participants with Treatment-Related adverse events as assessed by CTCAE v5.0 (Safety)
Time frame: 2 years

Sponsor's own description

The aim of this study is to assess safety, feasibility and immunogenicity of vaccination with neopeptide-loaded dendritic cells in Lynch Syndrome subjects who are known to be carrier of a germline MMR-gene mutation without signs of disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lynch Syndrome

Currently open trials in the same condition.

NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
NCT06582914 — Lynch Syndrome Integrative Epidemiology and Genetics · recruiting
NCT06447961 — PSYLIVED: the Psychological Impacts of Living With an Inherited Colorectal Cancer Predisposition Syndrome · recruiting
NCT05963191 — CAD-EYE System for the Detection of Neoplastic Lesions in Patients With Lynch Syndrome · NA · recruiting
NCT06712095 — Video Capsule Examination in Patients With Lynch Syndrome · NA · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07412197 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 30 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07412197.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing